Latest Human Genome Sciences Stories
VANCOUVER, British Columbia, Jan. 20, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Genworth Financial (NYSE:GNW), Suntech Power Holdings (NYSE:STP), Human Genome Sciences (NASDAQ:HGSI), Sirius (NASDAQ:SIRI), Amarin (NASDAQ:AMRN) and Hercules Offshore (NASDAQ:HERO). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to copy and...
VANCOUVER, British Columbia, Jan. 13, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Ford Motor (NYSE:F), Regions Financial (NYSE:RF), VIVUS (NASDAQ:VVUS), DDR (NYSE:DDR), Cemex (NYSE:CX) and Human Genome Sciences (NASDAQ:HGSI). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)...
BARCELONA, Spain, November 2, 2011 /PRNewswire/ -- In preparation for its European launch of Benlysta, the first FDA approved Lupus drug in 50 years, Human Genome Sciences (HGS) needed a customer relationship management (CRM) system to arm its newly formed European commercial sales team. The company had a long list of selection criteria including ease of use, flexibility, mobility, industry-specific functionality, speed, and low system maintenance. Veeva CRM - the fastest...
VANCOUVER, British Columbia, Aug. 10, 2011 /PRNewswire-Asia/ -- Insiderslab.com has issued Equity Research for the following companies today: Celgene (NASDAQ:CELG), Riverbed (NASDAQ:RVBD), Human Genome Sciences (NASDAQ:HGSI), Synovus (NYSE:SNV), Rackspace Hosting (NYSE:RAX) & Green Mountain (NASDAQ:GMCR). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) By following legal insider trading activity filed publicly with the SEC, the average investor may be better equipped to...
VANCOUVER, British Columbia, Aug. 8, 2011 /PRNewswire-Asia/ -- Insiderslab.com has issued Equity Research for the following companies today: CA (NASDAQ:CA), Riverbed (NASDAQ:RVBD), Human Genome Sciences (NASDAQ:HGSI), Citrix (NASDAQ:CTXS), Rackspace Hosting (NYSE:RAX) & Acme Packet (NASDAQ:APKT). Other than focusing on open-market insider transactions investors may sometimes have interesting opinions of those non-open market option-related purchases and sales. Insiders usually prefer to...
VANCOUVER, British Columbia, June 3, 2011 /PRNewswire-Asia/ -- Insiderslab.com helped investors filter out the noisy insider trade data. We issued valuable reports for OmniVision, Human Genome Sciences, International Paper, Tyco, Veeco, & Tyson today. Other than focusing on the open-market insider transactions, investors may sometimes have interesting opinions of those non-open market option-related purchases and sales. Insiders usually prefer to exercise their options rather than...
WASHINGTON, March 24, 2011 /PRNewswire/ -- Almost 3,000 walkers will celebrate the first drug developed for lupus in more than 50 years during the milestone 5th Annual Walk for Lupus Now! D.C. on Sat., April 16. Approved by the FDA on March 9, BENLYSTA by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) represents relief for the unrelenting pain faced by many lupus patients whose disease still lacks a cure. American Idol-ready Devin Kowl (http://www.devinkowl.com/), a 15-year-old...
SAN DIEGO, March 15, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the appointment of Barry A. Labinger to its Board of Directors. Mr. Labinger is Executive Vice President and Chief Commercial Officer of Human Genome Sciences. "We are very pleased to have Barry join our Board," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Anadys. "His impressive commercial credentials and product marketing savvy enhance our Board's collective...
The long path to Benlysta emphasizes importance of basic researchScientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues."I am deeply gratified that our scientific findings have proven so...
The US Food and Drug Administration (FDA) has approved Benlysta, making it the first new treatment for lupus to receive the agency's blessing in five decades.Benlysta is a drug that is taken by injection once per month. It is designed to help relieve pain and reduce the severity of symptoms associated with lupus--the mysterious disease in which the body's immune system turns on itself, attacking tissues and organs and leading to joint pain, chronic fatigue, arthritis, skin rashes, and in some...
